
Marcus SkribekKarolinska Institutet | KI · Department of Oncology-Pathology
Marcus Skribek
Doctor of Medicine
Clinical Oncologist and Postdoctoral Fellow focusing on improving lung cancer outcomes.
About
20
Publications
2,100
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
157
Citations
Introduction
As a Clinical Oncologist and Postdoctoral Fellow at Karolinska Institutet and Karolinska University Hospital, I focus on improving outcomes for lung cancer patients. I have clinical and research experience in lung cancer and immunotherapy. Passionate about improving patient outcomes, I actively contribute to the development of clinical guidelines and medical education.
Additional affiliations
January 2011 - June 2012
July 2013 - August 2013
July 2015 - August 2015
Education
September 2021 - February 2023
September 2012 - August 2018
Publications
Publications (20)
Immunotherapy with PD-1 or PD-L1 inhibitors has become an essential treatment strategy for a growing number of malignancies. These treatments have a risk for immune-related adverse events (IRAEs). Pooled analyses based on clinical trials show a favorable toxicity profile for treatment with PD-L1 compared to PD-1 inhibitors. This study aimed to inve...
Background: Lung cancer remains the leading cause of cancer-related mortality, with brain metastases (BMs) significantly worsening prognosis and quality of life. The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for non-small cell lung cancer (NSCLC). However, precise prognostic tools are essential to opti...
Purpose
When treating Lung Cancer, it is necessary to identify early treatment failure to enable timely therapeutic adjustments. The Aim of this study was to investigate whether changes in tumor diffusion during treatment with chemotherapy and bevacizumab could serve as a predictor of treatment failure.
Material and Methods
A prospective single-ar...
Background:
Real-World evidence on mesenchymal-epithelial transition exon 14 skipping mutations (METex14) in lung cancer remains limited. With an incidence of 3-4% across histological subtypes, METex14 is now an actionable target for MET inhibitors (METi) in advanced lung cancer, demonstrating response rates between 30-70%. Yet, its role in early...
Introduction: Lung cancer claims 1.6 million lives annually worldwide. In Sweden, there are roughly 1700 cases of stage IV Non-Small Cell Lung Cancer (NSCLC) yearly. The treatment landscape is evolving rapidly, necessitating a closer look at the parameters guiding physicians' choices. This study provides crucial insights, particularly for regions w...
Immune checkpoint inhibitors (ICIs) are associated with a wide range of immune-related adverse events. As oncological indications for ICIs widen, their rare side effects become increasingly visible in clinical practice and impact therapy decisions.
Here, we report a rare case of early-onset, mild cytokine release syndrome (CRS) in a patient who re...
Background: There is a paucity of real-world evidence addressing mesenchymal-epithelial transition exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC). Incidence is 3–4% for all histological subtypes. Recently, METex14 has emerged as a target lesion sensitive to MET inhibitors (METi) in advanced NSCLC, with overall response r...
Immune checkpoint inhibitors (ICIs) are associated with a wide range of immune-related adverse events (irAEs). As oncological indications for ICIs widen, their rare side effects become increasingly visible in clinical practice and impact therapy decisions.
Here, we provide a systematic review of the literature of CRS and related life-threatening si...
Background
Asian patients with metastatic non-small cell lung cancer (NSCLC) have a higher prevalence of epidermal growth factor receptor (EGFR) mutations compared to Caucasians, 30–50% and 15%, respectively. Osimertinib is a tyrosine kinase inhibitor approved as first-line therapy in patients with metastatic NSCLC harboring exon 19 or exon 21 EGFR...
The emergence of tyrosine kinase inhibitors and immune checkpoint inhibitors has paved a new era for the management of non-small cell lung cancer, which has for many years lacked major clinical breakthroughs. Historically, 5-year overall survival remained below 5% in individuals with metastatic disease. These novel treatments have led to significan...
There is a paucity of biomarkers for the prediction of intracranial (IC) outcome in immune checkpoint inhibitor (ICI)-treated non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM). We identified 280 NSCLC pts treated with ICIs at Karolinska University Hospital, Sweden, and University Hospital of Heraklion, Greece. The inclusi...
Introduction
We analysed patients with advanced non–small cell lung cancer (NSCLC) who were treated with immune-checkpoint inhibitors (ICIs) to address the effect of the timeline and reason for corticosteroid administration on survival outcomes.
Methods
We retrospectively collected clinical data of non-oncogenic driven, advanced NSCLC patients tre...
There is lack of data addressing the intracranial (IC) efficacy of immune checkpoint inhibitors (ICIs) on brain metastases (BM) in non-small cell lung cancer (NSCLC). This patient category is underrepresented in randomized clinical trials. We retrospectively collected clinical data on patients with non-oncogenic driven NSCLC with BM who were treate...
Background: The electrocardiogram (ECG) is a critical component of cardiovascular diagnosis. ECGs are standardly recorded in
the supine position; however, due to time and space constraints as well as patient limitations, they are often performed in other
positions (sitting, standing). Several studies have examined the effect of body position on ele...